Unnamed: 0,title,date,stock,sentiment
598373.0,Halozyme Announces J&J's Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX Utilizing Halozyme's ENHANZE Technology For The Treatment Of Patients With Multiple Myeloma,2020-06-04 12:38:00-04:00,HALO,neutral
598374.0,"Canaccord Genuity Maintains Buy on Halozyme Therapeutics, Raises Price Target to $27",2020-05-19 11:42:00-04:00,HALO,neutral
598375.0,"Cramer Weighs In On Ubiquiti, Callaway Golf And More",2020-05-15 08:08:00-04:00,HALO,neutral
598376.0,Halozyme To Receive $15 Million Milestone Payment From Janssen,2020-05-14 16:03:00-04:00,HALO,neutral
598377.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,HALO,neutral
598378.0,"JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $34",2020-05-12 11:31:00-04:00,HALO,positive
598379.0,"JP Morgan Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $23",2020-05-12 10:43:00-04:00,HALO,neutral
598380.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,HALO,neutral
598381.0,"BMO Capital Maintains Outperform on Halozyme Therapeutics, Raises Price Target to $35",2020-05-12 10:36:00-04:00,HALO,neutral
598382.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,HALO,negative
598383.0,32 Stocks Moving in Tuesday's Pre-Market Session,2020-05-12 07:16:00-04:00,HALO,neutral
598384.0,14 Stocks Moving In Monday's After-Hours Session,2020-05-11 17:19:00-04:00,HALO,neutral
598385.0,Halozyme Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.,2020-05-11 16:12:00-04:00,HALO,neutral
598386.0,"Halozyme Sees FY20 GAAP EPS $0.60-$0.75, Sales $230M-$245M",2020-05-11 16:02:00-04:00,HALO,neutral
598387.0,"Halozyme Therapeutics Q1 EPS $(0.040) Misses $(0.020) Estimate, Sales $25.354M Miss $42.960M Estimate",2020-05-11 16:01:00-04:00,HALO,negative
598388.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,HALO,neutral
598389.0,"EXUMA Biotech Is 'Revolutionizing CAR-T Therapy,' Increasing Patient Access, CEO Says",2020-05-06 12:42:00-04:00,HALO,neutral
598390.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,HALO,positive
598391.0,Halo Labs Experiences Delays In Regulatory Approval For California Dispensary,2020-05-04 15:10:00-04:00,HALO,positive
598392.0,Stocks That Hit 52-Week Highs On Monday,2020-05-04 10:35:00-04:00,HALO,neutral
598393.0,Halozyme Therapeutics shares are continuing higher after Janssen announced FDA approval of a multiple myeloma treatment which uses Halozyme's Enhanze technology.,2020-05-04 08:24:00-04:00,HALO,positive
598394.0,"Cantor Fitzgerald Reiterates Overweight on Halozyme Therapeutics, Raises Price Target to $39",2020-05-04 06:43:00-04:00,HALO,negative
598395.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2020-05-03 09:25:00-04:00,HALO,neutral
598396.0,"The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO",2020-05-01 07:54:00-04:00,HALO,neutral
598397.0,Halozyme Highlights Janssen's Receipt Of CHMP Positive Opinion For DARZALEX Subcutaneous Formulation Utilizing Halozyme's ENHANZE Technology For Patients With Multiple Myeloma,2020-04-30 16:56:00-04:00,HALO,positive
598398.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,HALO,positive
598399.0,Stocks That Hit 52-Week Highs On Tuesday,2020-04-28 10:18:00-04:00,HALO,neutral
598400.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,HALO,neutral
598401.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,HALO,neutral
598402.0,Halozyme shares are trading higher after the company announced Janssen submitted an NDA in Japan for Daratumumab Subcutaneous Formulation using Halozyme's ENHANZE technology.,2020-04-27 08:51:00-04:00,HALO,positive
598403.0,Halozyme Announces Janssen Submits NDA In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma,2020-04-27 05:45:00-04:00,HALO,neutral
598404.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,HALO,positive
598405.0,Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.,2020-04-23 11:27:00-04:00,HALO,positive
598406.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-23 10:41:00-04:00,HALO,neutral
598407.0,Shares of several healthcare companies are trading higher as equities gain amid oil prices potentially stabilizing following the recent crash.,2020-04-22 12:03:00-04:00,HALO,positive
598408.0,Halozyme 13G Filing From Artisan Partners Shows New 10.5% Stake,2020-04-09 09:50:00-04:00,HALO,neutral
598409.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,HALO,neutral
598410.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,HALO,positive
598411.0,10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades,2020-03-17 17:13:00-04:00,HALO,neutral
598412.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,HALO,negative
598413.0,"Barclays Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $20",2020-02-25 11:40:00-05:00,HALO,neutral
598414.0,"JP Morgan Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $22",2020-02-25 08:40:00-05:00,HALO,negative
598415.0,Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta And Herceptin Using Enhanze Technology,2020-02-25 05:22:00-05:00,HALO,positive
598416.0,"Halozyme Reaffirms FY20 Guidance: GAAP EPS $0.60-$0.75, Sales $230M-$245M vs $220.7M Estimate",2020-02-24 16:03:00-05:00,HALO,neutral
598417.0,"Halozyme Therapeutics Q4 EPS $(0.24) Misses $(0.15) Estimate, Sales $53.665M Miss $56.93M Estimate",2020-02-24 16:02:00-05:00,HALO,negative
598418.0,Halozyme Reports CFO Laurie Stelzer Resigned; Elaine Sun Named Replacement,2020-02-24 16:02:00-05:00,HALO,negative
598419.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,HALO,neutral
598420.0,Stocks That Hit 52-Week Highs On Friday,2020-02-21 10:26:00-05:00,HALO,neutral
598421.0,"The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion",2020-02-21 07:46:00-05:00,HALO,negative
598422.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,HALO,negative
598423.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-18 11:03:00-05:00,HALO,neutral
598424.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,HALO,negative
598425.0,Halozyme Therapeutics shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised the price target from $18 to $27 per share.,2020-02-05 10:25:00-05:00,HALO,positive
598426.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-05 10:16:00-05:00,HALO,neutral
598427.0,"Benzinga's Top Upgrades, Downgrades For February 5, 2020",2020-02-05 09:55:00-05:00,HALO,positive
598428.0,"Piper Sandler Upgrades Halozyme Therapeutics to Overweight, Raises Price Target to $27",2020-02-05 05:27:00-05:00,HALO,negative
598429.0,10 Biggest Price Target Changes For Monday,2020-01-27 08:56:00-05:00,HALO,neutral
598430.0,"Cantor Fitzgerald Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $35",2020-01-27 07:35:00-05:00,HALO,negative
598431.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,HALO,negative
598432.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,HALO,neutral
598433.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,HALO,neutral
598434.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-15 13:14:00-05:00,HALO,neutral
598435.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,HALO,negative
598436.0,Halozyme Therapeutics shares are trading higher after the company issued FY20 sales guidance above analyst estimates. The company also added $150 million to its buyback.,2020-01-14 13:56:00-05:00,HALO,positive
598437.0,Halozyme Adds $150M to Buyback,2020-01-14 08:11:00-05:00,HALO,neutral
598438.0,Halozyme Sees FY20 Sales $230M-$245M vs $227.01M Est.,2020-01-14 08:07:00-05:00,HALO,neutral
598439.0,Halozyme Provides 2020 Business Update And Financial Guidance,2020-01-14 08:07:00-05:00,HALO,neutral
598440.0,10 Biggest Price Target Changes For Thursday,2020-01-09 10:43:00-05:00,HALO,neutral
598441.0,"Benzinga's Top Upgrades, Downgrades For January 9, 2020",2020-01-09 10:34:00-05:00,HALO,positive
598442.0,Halozyme Therapeutics shares are trading higher after BMO Capital upgraded the stock from Market Perform to Outperform and raised the price target from $17 to $24 per share.,2020-01-09 10:11:00-05:00,HALO,positive
598443.0,"BMO Capital Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $24",2020-01-09 09:09:00-05:00,HALO,neutral
598444.0,"UPDATE: Goldman On Haloyzme Notes Co. 'is further de-risked, in that Enhanze is a proven technology: HALO has nine partnerships with top biopharma (including Roche, JNJ, ARGX, and ALXN) for it, and Enhanze is already used in three approved products'",2020-01-08 13:40:00-05:00,HALO,positive
598445.0,"UPDATE: Goldman Initiates Halozyme Therapeutics With Buy, $24 Target Notes 'Moving away from its own drugs, a newer, simpler and low(er) risk biotech story emerges'",2020-01-08 13:34:00-05:00,HALO,negative
598446.0,Halozyme Therapeutics shares are trading higher after Goldman Sachs initiated coverage on the stock with a Buy rating and announced a $24 price target.,2020-01-08 09:42:00-05:00,HALO,positive
598447.0,"Goldman Sachs Initiates Coverage On Halozyme Therapeutics with Buy Rating, Announces $24 Price Target",2020-01-08 06:45:00-05:00,HALO,neutral
598448.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,HALO,neutral
598449.0,Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium,2019-12-12 05:07:00-05:00,HALO,negative
598450.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,HALO,positive
598451.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,HALO,neutral
598452.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,HALO,positive
598453.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-20 10:12:00-05:00,HALO,neutral
598454.0,"Cantor Fitzgerald Reiterates Overweight on Halozyme Therapeutics, Raises Price Target to $27",2019-11-20 07:28:00-05:00,HALO,negative
598455.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,HALO,positive
598456.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-19 10:21:00-05:00,HALO,neutral
598457.0,Stocks That Hit 52-Week Highs On Friday,2019-11-15 10:14:00-05:00,HALO,neutral
598458.0,"The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval",2019-11-15 07:08:00-05:00,HALO,negative
598459.0,Halozyme Therapeutics shares are trading higher despite pricing its private offering of $400 million of convertible senior notes. The stock is trading on approximately 12X higher-than-average volume.,2019-11-14 11:51:00-05:00,HALO,positive
598460.0,Stocks That Hit 52-Week Highs On Thursday,2019-11-14 10:09:00-05:00,HALO,neutral
598461.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,HALO,positive
598462.0,"BMO Capital Maintains Market Perform on Halozyme Therapeutics, Raises Price Target to $17",2019-11-13 09:01:00-05:00,HALO,neutral
598463.0,"JP Morgan Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $23",2019-11-13 08:24:00-05:00,HALO,neutral
598464.0,"Halozyme Therapeutics Q3 EPS $(0.17) Misses $(0.12) Estimate, Sales $46.23M Miss $54.81M Estimate",2019-11-12 16:46:00-05:00,HALO,negative
598465.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,HALO,neutral
598466.0,"Benzinga's Top Upgrades, Downgrades For November 5, 2019",2019-11-05 10:00:00-05:00,HALO,positive
598467.0,"Barclays Upgrades Halozyme Therapeutics to Equal-Weight, Lowers Price Target to $16",2019-11-05 06:38:00-05:00,HALO,negative
598468.0,"Halozyme Scraps Oncology Program Following Failed Study, Charts Out Profitability Plan",2019-11-04 09:56:00-05:00,HALO,negative
598469.0,"Halozyme's Phase 3 Study of PEGPH20 Misses its Primary Endpoint, Company to Halt Oncology Operations in Effort to Achieve $130M to $140M of Annual Cost Savings",2019-11-04 07:06:00-05:00,HALO,negative
598470.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,HALO,neutral
598471.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,HALO,negative
598472.0,"The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans",2019-09-13 07:40:00-04:00,HALO,neutral
598473.0,Halozyme Announces Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology,2019-09-13 03:50:00-04:00,HALO,positive
598474.0,"Halozyme Therapeutics Q2 EPS $(0.10) Beats $(0.14) Estimate, Sales $39.148M Miss $42.76M Estimate",2019-08-06 16:12:00-04:00,HALO,negative
598475.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,HALO,positive
598476.0,Halozyme Reports J&J's Janssen Submitted Extension Application To EMA For Subcutaneous Formulation Of DARZALEX Utilizing ENHANZE Technology,2019-07-19 07:03:00-04:00,HALO,neutral
598477.0,Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE Drug Delivery Technology,2019-07-17 08:01:00-04:00,HALO,neutral
598478.0,Halozyme Therapeutics Reports J&J's Janssen Submitted Biologics License Application To FDA For Subcutaneous Delivery Of DARZALEX For Patients With Multiple Myeloma,2019-07-12 12:01:00-04:00,HALO,neutral
598479.0,Halozyme Announces CRADA With National Institute Of Allergy And Infectious Diseases For Use Of ENHANZE Drug Delivery Technology,2019-06-25 08:08:00-04:00,HALO,neutral
598480.0,"The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study",2019-05-22 07:34:00-04:00,HALO,neutral
598481.0,Halozyme Announces argenx Has Selected Second Target Under ENHANZE Technology Collaboration And License Agreement; Triggers $10M Milestone Payment,2019-05-22 03:54:00-04:00,HALO,positive
598482.0,Halozyme Therapeutics Guides FY19 Revenues Of $205M-$215M Vs. $209.09M Estimate,2019-05-07 17:32:00-04:00,HALO,neutral
598483.0,"Halozyme Therapeutics Q1 EPS $0.01, Inline, Sales $56.949M Miss $67.8M Estimate",2019-05-07 17:31:00-04:00,HALO,negative
598484.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,HALO,neutral
598485.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,HALO,negative
598486.0,Halozyme Reports FDA Approval Of Herceptin Hylecta,2019-02-28 11:51:00-05:00,HALO,positive
598487.0,Halozyme Therapeutics Sees FY19 Sales $205M-$215M vs $168.78M Est.,2019-02-21 16:05:00-05:00,HALO,neutral
598488.0,"Halozyme Therapeutics Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $60.2M Beat $59.94M Estimate",2019-02-21 16:05:00-05:00,HALO,neutral
598489.0,"The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan",2019-02-21 07:32:00-05:00,HALO,positive
598490.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2019-02-15 14:00:00-05:00,HALO,neutral
598491.0,Halozyme Therapeutics shares are trading higher after the company announced it entered a global collaboration and license agreement with Argenx for the use of ENHANZE Technology.,2019-02-04 09:28:00-05:00,HALO,positive
598492.0,"Argenx, Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology",2019-02-04 03:58:00-05:00,HALO,positive
598493.0,Halozyme Provides 2019 Pipeline Update At 37th Annual JP Morgan Healthcare Conference,2019-01-09 13:37:00-05:00,HALO,positive
598494.0,Halozyme Sees FY19 Sales $175M-$185M vs $152.57M Est.,2019-01-09 13:36:00-05:00,HALO,neutral
598495.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,HALO,positive
598496.0,48 Biggest Movers From Yesterday,2018-11-28 05:00:00-05:00,HALO,neutral
598497.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-11-27 12:25:00-05:00,HALO,neutral
598498.0,Halozyme Therapeutics shares are trading down 7.2% after the company agreed to change the efficacy endpoint measure in its Phase 3 clinical trial of PEGPH20.,2018-11-27 12:21:00-05:00,HALO,positive
598499.0,32 Stocks Moving In Tuesday's Pre-Market Session,2018-11-27 08:00:00-05:00,HALO,neutral
598500.0,"The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial",2018-11-27 07:32:00-05:00,HALO,negative
598501.0,Halozyme shares down 16.6% as company adjusted the qualification for its endpoint of its HALO-301 trial to a single primary endpoint of overall survival,2018-11-26 17:39:00-05:00,HALO,positive
598502.0,"Halozyme Shares Resume Trade, Down 3%",2018-11-26 16:35:00-05:00,HALO,positive
598503.0,Halozyme Shares To Resume Trade At 4:35 p.m. EST,2018-11-26 16:08:00-05:00,HALO,positive
598504.0,Halozyme Changes Primary Endpoint In HALO-301 Trial To Single Primary Endpoint Of Overall Survival,2018-11-26 16:06:00-05:00,HALO,neutral
598505.0,Halozyme Therapeutics Shares Halted News Pending,2018-11-26 16:01:00-05:00,HALO,positive
598506.0,Halozyme Therapeutics Raises FY18 Sales Guidance From $125M-$135M To $150M-$160M vs $126.97M Est.; NOTE:  Guidance Raise Driven By $25M Upfront Payment From Roche ENHANZE Agreement,2018-11-06 17:14:00-05:00,HALO,positive
598507.0,"Halozyme Therapeutics, Inc. Q3 EPS $(0.19) Beats $(0.23) Estimate, Sales $25.56M Miss $30.42M Estimate",2018-11-06 17:12:00-05:00,HALO,negative
598508.0,A Preview Of Halozyme Therapeutics Q3 Earnings,2018-11-06 09:23:00-05:00,HALO,neutral
598509.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,HALO,positive
598510.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,HALO,neutral
598511.0,Halozyme Licenses New ENHANZE Targets For $25 Million Upfront Payment And Up To $265M In Future Milestones And Royalties,2018-10-30 08:05:00-04:00,HALO,neutral
598512.0,Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze Technology; Initiation Of Study Triggered $5M Milestone Payment To Halozyme,2018-10-25 08:23:00-04:00,HALO,neutral
598513.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,HALO,negative
598514.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,HALO,negative
598515.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,HALO,negative
598516.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,HALO,positive
598517.0,26 Stocks Moving In Tuesday's Pre-Market Session,2018-10-09 08:19:00-04:00,HALO,neutral
598518.0,Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab From Health Canada,2018-09-17 08:01:00-04:00,HALO,positive
598519.0,"Cantor Fitzgerald Initiates Coverage On Halozyme Therapeutics with Overweight Rating, Announces $27 Price Target",2018-08-23 07:08:00-04:00,HALO,negative
598520.0,"Halozyme Therapeutics Q2 EPS $(0.16) Beats $(0.22) Estimate, Sales $35.2M Beat $30.09M Estimate",2018-08-07 16:29:00-04:00,HALO,neutral
598521.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,HALO,negative
598522.0,Phase 3 Study Of Roche's Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE Technology,2018-07-26 08:02:00-04:00,HALO,neutral
598523.0,Halozyme Therapeutics Reports FDA Acceptance Of Biologics License Application For Subcutaneous Formulation Of Herceptin,2018-07-11 08:35:00-04:00,HALO,positive
598524.0,50 Biggest Movers From Friday,2018-05-14 05:07:00-04:00,HALO,neutral
598525.0,38 Stocks Moving In Friday's Mid-Day Session,2018-05-11 12:28:00-04:00,HALO,neutral
598526.0,"Benzinga's Top Upgrades, Downgrades For May 11, 2018",2018-05-11 09:38:00-04:00,HALO,positive
598527.0,"Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again",2018-05-11 08:21:00-04:00,HALO,negative
598528.0,22 Stocks Moving In Friday's Pre-Market Session,2018-05-11 08:03:00-04:00,HALO,neutral
598529.0,Barclays Downgrades Halozyme Therapeutics to Underweight,2018-05-11 07:20:00-04:00,HALO,neutral
598530.0,Halozyme Therapeutics Reaffirms FY18 Outlook; Sees Sales $115M-$125M vs $137.01M Est.,2018-05-10 17:23:00-04:00,HALO,neutral
598531.0,"Halozyme Therapeutics Q1 EPS $(0.19) Beats $(0.22) Estimate, Sales $30.872M Miss $31.43M Estimate",2018-05-10 17:22:00-04:00,HALO,negative
598532.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,HALO,neutral
598533.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,HALO,neutral
598534.0,24 Stocks Moving In Monday's Pre-Market Session,2018-04-23 08:02:00-04:00,HALO,neutral
598535.0,Halozyme Reaffirms FY18 Sales Outlook: $115M-$125M vs $139.5M Est.,2018-02-20 16:12:00-05:00,HALO,neutral
598536.0,"Halozyme Therapeutics Reports Q4 EPS $0.85 vs $0.72 Est., Sales $189.6M vs $165.2M Est.",2018-02-20 16:12:00-05:00,HALO,neutral
598537.0,Halozyme Option Alert: Mar 16 $18 Calls Sweep (2) at the Bid: 600 @ $1.301 vs 1865 OI; Earnings 2/20 After Close Ref=$18.53,2018-02-20 15:21:00-05:00,HALO,positive
598538.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-19 10:50:00-05:00,HALO,neutral
598539.0,32 Stocks Moving In Wednesday's Mid-Day Session,2018-01-24 12:27:00-05:00,HALO,neutral
598540.0,"Benzinga's Top Upgrades, Downgrades For January 24, 2018",2018-01-24 09:27:00-05:00,HALO,positive
598541.0,"Goldman Sachs Initiates Coverage On Halozyme Therapeutics with Neutral Rating, Announces $20.00 Price Target",2018-01-24 08:28:00-05:00,HALO,neutral
598542.0,44 Biggest Movers From Yesterday,2018-01-18 04:43:00-05:00,HALO,neutral
598543.0,Halozyme Therapeutics Shares Down 11.32% Following Release Of SWOG Abstract Suggesting The Co's PEGPH20 In Combination With mFFOX Shows No Beneift And Appears To Be Detrimental; Hearing Deutsche Bank Lowered Price Target From $21 to $19 In Response,2018-01-17 12:38:00-05:00,HALO,negative
598544.0,38 Stocks Moving In Wednesday's Mid-Day Session,2018-01-17 12:28:00-05:00,HALO,neutral
598545.0,30 Stocks Moving In Wednesday's Pre-Market Session,2018-01-17 08:01:00-05:00,HALO,neutral
598546.0,"Halozyme Late Tuesday Announced It Sees 25-30% Royalty Revenue Growth In 2018, Potential For Royalty Revenue To Reach ~$1B In 2027",2018-01-10 09:19:00-05:00,HALO,positive
598547.0,Halozyme Option Alert: Jan 19 $20 Puts Sweep (30) at the Ask: 504 @ $0.801 vs 5597 OI; Ref=$20.6141,2017-12-28 14:31:00-05:00,HALO,positive
598548.0,"Lightning Round: Jim Cramer Weighs In On Groupon, First Solar, Roku, And More",2017-12-19 06:52:00-05:00,HALO,neutral
598549.0,"Alexion and Halozyme Enter License Agreement for ENHANZE, Halozyme to Receive a $40M Upfront Payment",2017-12-07 06:31:00-05:00,HALO,positive
598550.0,"Barclays Assumes Halozyme Therapeutics at Equal-Weight, Announces price target $19.00",2017-11-22 11:01:00-05:00,HALO,neutral
598551.0,Halozyme Option Alert: Jan 19 $19 Calls at the Bid: 1000 @ $1.2 vs 1374 OI; Ref=$19.03,2017-11-10 10:18:00-05:00,HALO,positive
598552.0,"Lightning Round: Jim Cramer Advises His Viewers On Gilead, Exxon Mobil And More",2017-11-09 07:30:00-05:00,HALO,neutral
598553.0,Halozyme Therapeutics Shares Up 13.12% After Co. Tuesday Reported Impressive Q3 Beat and FY17 Guidance Raise,2017-11-08 15:06:00-05:00,HALO,positive
598554.0,Halozyme Raises FY17 Sales Guidance From $245M-$260M To $265M-$280M vs $259M Est.,2017-11-07 17:34:00-05:00,HALO,neutral
598555.0,"Halozyme Reports Q3 EPS $0.02 vs $(0.23) In Same Qtr. Last Year, Sales $63.7M vs $59M Est.",2017-11-07 17:33:00-05:00,HALO,neutral
598556.0,UPDATE: Halozyme Will Receive $15M Milestone Payment From J&J's Janssen Following Dosing Of 3rd Patient In Phase 3 Trial,2017-10-31 08:40:00-04:00,HALO,neutral
598557.0,Halozyme Therapeutics Reports Phase 3 Study Of Subcutanous Daratumumab Initiated Using Co.'s ENHANZE Technology,2017-10-31 08:39:00-04:00,HALO,neutral
598558.0,Halozyme Reports First Gastric Cancer Patient Dosed In Trial Collaboration Evaluating Co.'s PEGPH20 In Combo With Anti-PDL1 Immunotherapy,2017-10-24 08:34:00-04:00,HALO,negative
598559.0,10 Stocks Moving In Monday's After-Hours Session,2017-10-16 17:03:00-04:00,HALO,neutral
598560.0,Halozyme Initiates Trial of PEGPH20,2017-10-16 08:02:00-04:00,HALO,neutral
598561.0,Watch These 5 Huge Call Purchases In Friday Trade,2017-09-15 04:25:00-04:00,HALO,positive
598562.0,Benzinga's Option Alert Recap From September 14,2017-09-14 16:03:00-04:00,HALO,positive
598563.0,Halozyme Option Alert: Jan 19 $16 Calls at the Bid: 919 @ $1.15 vs 314 OI; Ref=$15.6,2017-09-14 15:47:00-04:00,HALO,positive
598564.0,Mid-Afternoon Market Update: Dow Gains 50 Points; Glaukos Shares Slide,2017-09-14 14:32:00-04:00,HALO,positive
598565.0,15 Biggest Mid-Day Gainers For Thursday,2017-09-14 12:33:00-04:00,HALO,neutral
598566.0,Mid-Day Market Update: Crude Oil Up Over 2%; Summit Therapeutics Shares Plunge,2017-09-14 12:05:00-04:00,HALO,negative
598567.0,Mid-Morning Market Update: Markets Mostly Lower; United Natural Foods Profit Beats Expectations,2017-09-14 10:12:00-04:00,HALO,positive
598568.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-09-14 08:06:00-04:00,HALO,neutral
598569.0,Halozyme Therapeutics Raises fy Sales Guidance from $115.0M-130.0M to $245.0M-260.0M vs $131.90M Est,2017-09-14 07:08:00-04:00,HALO,neutral
598570.0,Halozyme Announces the Licensing of its ENHANZE to Roche for $30M Upfront,2017-09-14 07:07:00-04:00,HALO,neutral
598571.0,"Bristol-Myers and Halozyme Enter Collaboration and License Agreement Using Halozyme's ENHANZE, Halozyme to Receive $105M Upfront",2017-09-14 07:00:00-04:00,HALO,positive
598572.0,"Secondary Offering Lockup Expirations Today From Halozyme Therapeutics, Indentiv, and Harte Hanks",2017-08-17 08:52:00-04:00,HALO,neutral
598573.0,"Halozyme Reports Q2 Loss/Share $(0.23) vs. $(0.24) Est., Sales $33.8M vs. $31.76M Est.",2017-08-08 16:23:00-04:00,HALO,neutral
598574.0,Halozyme Report Start Of Multi-Arm Clinical Trial Evaluating PEGPH20 In Combination With atezolizumab,2017-07-13 08:32:00-04:00,HALO,neutral
598575.0,Halozyme Therapeutics New Safety Data Show Bleeding Events Balanced Between 2 Arms After Introduction of Low Molecular Weight Heparin In Stage 2 of Study,2017-06-28 12:02:00-04:00,HALO,positive
598576.0,Benzinga's Option Alert Recap From June 15,2017-06-15 16:05:00-04:00,HALO,positive
598577.0,Option Alert: Halozyme Jul 15.0 Calls Sweep: 1000 @  ASK  $0.15: 1054 traded vs 320 OI:  Earnings 8/8 After Close (est)  $12.88 Ref,2017-06-15 11:20:00-04:00,HALO,positive
598578.0,Halozyme Announces Encouraging Phase 2 Data In Advanced Pancreas Cancer Featured in Oral Presentation #ASCO17,2017-06-04 17:48:00-04:00,HALO,neutral
598579.0,Mid-Afternoon Market Update: Dow Climbs 150 Points; Foot Locker Shares Drop On Earnings Miss,2017-05-19 14:30:00-04:00,HALO,negative
598580.0,10 Biggest Mid-Day Losers For Friday,2017-05-19 13:10:00-04:00,HALO,negative
598581.0,Mid-Day Market Update: Crude Oil Up 2%; Halozyme Therapeutics Shares Plunge,2017-05-19 12:16:00-04:00,HALO,negative
598582.0,Mid-Morning Market Update: Markets Open Higher; Deere Earnings Beat Views,2017-05-19 10:07:00-04:00,HALO,neutral
598583.0,Halozyme Shares Move to Premarket High of $13.05; Co Priced 10M Share Offering @$12.50/Share,2017-05-19 08:19:00-04:00,HALO,positive
598584.0,22 Stocks Moving In Friday's Pre-Market Session,2017-05-19 08:11:00-04:00,HALO,neutral
598585.0,Halozyme Therapeutics Reports $100M Offering Common Stock,2017-05-18 16:08:00-04:00,HALO,neutral
598586.0,"Halozyme Says HALO-202 Study Met Primary, Key Secondary Endpoints, Showed Statistically Significant Improvement in Progression-Free Survival in Patients with High Levels of Hyaluronan",2017-05-17 17:31:00-04:00,HALO,positive
598587.0,Halozyme SeesFY17 Sales $115-$130M vs $132M Est.,2017-05-09 16:13:00-04:00,HALO,neutral
598588.0,"Halozyme Reports Q1 EPS $(0.26) vs $(0.25) Est., Sales $29.6M vs $30.8M Est.",2017-05-09 16:13:00-04:00,HALO,neutral
598589.0,"Benzinga's Top Upgrades, Downgrades For April 17, 2017",2017-04-17 09:34:00-04:00,HALO,positive
598590.0,"BMO Capital Initiates Coverage On Halozyme Therapeutics with Market Perform Rating, Announces $14.00 Price Target",2017-04-17 08:19:00-04:00,HALO,neutral
598591.0,"Halozyme Reports PEGPH20 Increases Immune Response, Effectiveness of Immunotherapies in Preclinical Cancer Models",2017-04-03 08:06:00-04:00,HALO,negative
598592.0,15 Biggest Mid-Day Losers For Thursday,2017-03-30 13:03:00-04:00,HALO,negative
598593.0,Halozyme Therapeutics Falls After Group Clinical Study Closed To Enrollment,2017-03-30 09:55:00-04:00,HALO,neutral
598594.0,"Halozyme Therapeutics Says SWOG Collaborative Group Clinical Study Temporarily Closed To Enrollment,",2017-03-30 08:32:00-04:00,HALO,neutral
598595.0,Halozyme Therapeutics Reports FDA Panel Provided Unanimous Recommendation for Rituximab Coformulated with Halozyme's Enhanze Technology,2017-03-29 12:45:00-04:00,HALO,neutral
598596.0,"Halozyme Reports Q4 EPS $(0.21) vs. $(0.28) Est., Sales $39M vs. $38.3M",2017-02-28 16:43:00-05:00,HALO,neutral
598597.0,Benzinga's Option Alert Recap From February 24,2017-02-24 16:40:00-05:00,HALO,positive
598598.0,Option Alert: Halozyme Jun 17.0 Calls Sweep: 500 @  ASK  $0.30: 500 traded vs 2368 OI:  Earnings 2/28 After Close  $12.00 Ref,2017-02-24 10:06:00-05:00,HALO,positive
598599.0,UPDATE: MabVax Says MVT-5873 Demonstrated Improvement in Accumulation on Tumors in An Animal Model of Pancreatic Cancer,2017-02-13 08:34:00-05:00,HALO,negative
598600.0,MabVax Therapeutics Reports Studies Lead Investigational MVT-5873 with Halozyne PEGPH20,2017-02-13 08:33:00-05:00,HALO,neutral
598601.0,First Eagle Investment Management Reports 5.94% Stake In Halozyme Therapeutics,2017-02-06 16:52:00-05:00,HALO,neutral
598602.0,Option Alert: Halozyme Mar 12.0 Call: 3838 @  BID @ $1.26;  $13.94 Ref,2017-01-11 14:05:00-05:00,HALO,positive
598603.0,Option Alert: Halozyme Jan 11.0 Puts Sweep: 510 @  ASK  $0.10: 510 traded vs 1968 OI:  Earnings 2/27 After Close (est)  $12.51 Ref,2017-01-11 11:25:00-05:00,HALO,positive
598604.0,15 Biggest Mid-Day Losers For Tuesday,2017-01-10 13:24:00-05:00,HALO,negative
598605.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-01-10 08:24:00-05:00,HALO,neutral
598606.0,"Halozyme Says Expects to Make Continued Progress Showing Pan-Tumor Potential of PEGPH20, Focus on Near-Term Catalysts in ENHANZE Platform",2017-01-09 16:11:00-05:00,HALO,positive
598607.0,Halozyme Sees FY17 Sales $115M-$130M vs $146M Est.,2017-01-09 16:10:00-05:00,HALO,neutral
598608.0,15 Biggest Mid-Day Gainers For Thursday,2017-01-05 12:38:00-05:00,HALO,neutral
598609.0,Halozyme Surrenders Most Of Its Pre-Market Gains,2017-01-05 11:59:00-05:00,HALO,positive
598610.0,"Halozyme Achieves Endpoint In Pancreatic Cancer Study, But Not Everyone Is Bullish",2017-01-05 09:56:00-05:00,HALO,negative
598611.0,"Adam Feuerstein Tweets: And we wonder why biotech industry has poor reputation for transparency and honest disclosure of data. Stop the nonsense, $HALO.",2017-01-05 08:51:00-05:00,HALO,negative
598612.0,"Adam Feuerstein Tweets: $HALO Shameful conduct this morning. Press release cherry picks single, most positive data point, omits everything else less so.",2017-01-05 08:50:00-05:00,HALO,positive
598613.0,"Adam Feuerstein @adamfeuerstein Tweet: $HALO stage 1 data, stage 2 data, stage 1/2 combined, HA high, HA low, ITT, evaluable, etc.  Throw all against wall, hope something sticks.",2017-01-05 08:23:00-05:00,HALO,positive
598614.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-01-05 08:23:00-05:00,HALO,neutral
598615.0,Adam Feuerstein Tweets: $HALO data are muddled mess. Listening to the call.,2017-01-05 08:20:00-05:00,HALO,negative
598616.0,"Adam Feuerstein Tweets: $HALO followers, did you read the PR closely? Seems like they're only reporting positive results from a subset of pancreatic cancer pats.",2017-01-05 07:37:00-05:00,HALO,positive
598617.0,Halozyme +54% Premarket @$16.45; Co Announced Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints,2017-01-05 07:34:00-05:00,HALO,negative
598618.0,Halozyme Achieves Endpoint in Phase 2 Study In Advanced Pancreas Cancer,2017-01-05 07:03:00-05:00,HALO,negative
598619.0,Halozyme Phase 2 Study Meets Primary Endpoints,2017-01-05 07:00:00-05:00,HALO,neutral
598620.0,Watch These 4 Huge Put Purchases In Wednesday Trade,2016-12-21 04:12:00-05:00,HALO,positive
598621.0,Option Alert: Halozyme Jan 10.0 Puts Sweep: 726 @  ASK  $0.799: 3305 traded vs 564 OI:  Earnings 2/27 After Close (est)  $11.36 Ref,2016-12-20 12:49:00-05:00,HALO,positive
598622.0,"Halozyme Reports AbbVie Discontinues Development Program Using ENHANZE Platform, Will Continue To Identify Additional Targets Under 2015 Partnership And Licensing Agreement",2016-11-21 08:33:00-05:00,HALO,positive
598623.0,"Halozyme Reports Broad Clinical Collaboration Deal to Evaluate PEGPH20, Tecentriq in Up to Eight Tumor Types",2016-11-10 08:31:00-05:00,HALO,negative
598624.0,Halozyme Therapeutics Sees FY16 Rev. $145-$150M vs. Est. $148.8M,2016-11-07 16:08:00-05:00,HALO,neutral
598625.0,"Halozyme Therapeutics Reports Q3 EPS $(0.23) vs. Est. $(0.27), Rev. $31.9M vs. Est. $33.8M",2016-11-07 16:08:00-05:00,HALO,neutral
598626.0,Watch These 5 Huge Call Purchases In Friday Trade,2016-11-04 03:02:00-04:00,HALO,positive
598627.0,Option Alert: HALO Jan17 10.0 Calls Sweep: 1342 @  ASK  $1.20: 1348 traded vs 5832 OI:  Earnings 11/7 After Close  $8.48 Ref,2016-11-03 14:03:00-04:00,HALO,positive
598628.0,Benzinga's Top Initiations,2016-11-03 09:21:00-04:00,HALO,positive
598629.0,FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab,2016-11-03 08:35:00-04:00,HALO,positive
598630.0,"Deutsche Bank Initiates Coverage On Halozyme Therapeutics, Inc. - Common Stock at Buy",2016-11-03 06:05:00-04:00,HALO,neutral
598631.0,10 Stocks That Plummeted The Past Three Days On Increasing Volume,2016-10-31 07:13:00-04:00,HALO,neutral
598632.0,Option Alert: HALO Nov $13 Call Sweep; 755 @ Ask @$0.23,2016-10-17 10:58:00-04:00,HALO,positive
598633.0,Watch These 5 Huge Put Purchases In Monday Trade,2016-10-17 02:56:00-04:00,HALO,positive
598634.0,Option Alert: HALO Nov16 9.0 Puts: 3000 @  ASK  $0.50: 3000 traded vs 15 OI:  Earnings 11/14  $10.32 Ref,2016-10-14 12:17:00-04:00,HALO,positive
598635.0,Halozyme Drug PEGPH20 Included In Precision Promise Pancreatic Cancer Study,2016-10-04 06:16:00-04:00,HALO,negative
598636.0,"25 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-22 09:47:00-04:00,HALO,neutral
598637.0,Halozyme Names Mark Gergen COO,2016-09-01 09:05:00-04:00,HALO,neutral
598638.0,"Halozyme Raises FY16 Outlook: Sales from $130M-$145M to $140M-$150M vs $138.7M Est., Cash Flow from $45M-$65M to $65M-$85M",2016-08-09 17:13:00-04:00,HALO,neutral
598639.0,"Halozyme Q2 EPS $(0.21) vs $(0.27) Est., Sales $33.3M vs $29.9M Est.",2016-08-09 17:13:00-04:00,HALO,neutral
598640.0,Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA,2016-07-25 09:06:00-04:00,HALO,neutral
598641.0,UPDATE: Halozyme Raises '16 Year-End Cash Balance Outlook from $150M-$170M to $170M-$190M,2016-06-08 09:03:00-04:00,HALO,neutral
598642.0,"Halozyme Reports Deal to Refinance Debt, Raises '16 Outlook for Year-End Cash Balance",2016-06-08 09:02:00-04:00,HALO,negative
598643.0,Mid-Morning Market Update: Markets Open Higher; Devon Energy To Sell Non-Core Upstream Assets For Around $1 Billion,2016-06-06 10:09:00-04:00,HALO,positive
598644.0,Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 at #ASCO16,2016-06-04 10:03:00-04:00,HALO,negative
598645.0,Halozyme Rasises FY 2016 Guidance; Sees Revenue $130M to $145M vs $127.89M est,2016-05-09 17:38:00-04:00,HALO,neutral
598646.0,"Halozyme Q1 EPS ($0.16) vs ($0.20) est, Revenue $42.50M vs $26.65M, May Not Compare",2016-05-09 17:38:00-04:00,HALO,neutral
598647.0,"Halozyme Reports Dosing of First Patient in Phase 3 Trial of PEGPH20 in Combo with ABRAXANE, Gemcitabine",2016-03-16 08:38:00-04:00,HALO,neutral
598648.0,Mid-Morning Market Update: Markets Open Higher; Dollar Tree Misses Q4 Views,2016-03-01 10:11:00-05:00,HALO,negative
598649.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-03-01 08:24:00-05:00,HALO,neutral
598650.0,7 Stocks Moving In Today's After-Hours Session,2016-02-29 18:01:00-05:00,HALO,neutral
598651.0,Halozyme Sees FY Revenue $110M to $125M vs $120.2M est,2016-02-29 16:08:00-05:00,HALO,neutral
598652.0,"Halozyme Q4 EPS $0.03 vs ($0.08) est, Revenue $52.2M vs $42.1M est",2016-02-29 16:08:00-05:00,HALO,neutral
598653.0,"Earnings Scheduled For February 29, 2016",2016-02-29 04:04:00-05:00,HALO,neutral
598654.0,"CORRECTION: Barclays Maintains Overweight on Halozyme Therapeutics, Lowers PT to $16.00",2016-02-24 06:24:00-05:00,HALO,negative
598655.0,"Barclays Maintains Overweight on Halozyme Therapeutics, Lowers PT to $16.00",2016-02-24 05:26:00-05:00,HALO,negative
598656.0,Benzinga's Top Initiations,2016-02-01 09:52:00-05:00,HALO,positive
598657.0,Canaccord Genuity Initiates Coverage on Halozyme Therapeutics at Buy,2016-02-01 07:55:00-05:00,HALO,neutral
598658.0,Halozyme Confirms $5 Million Milestone Payment From AbbVie,2016-01-21 14:54:00-05:00,HALO,neutral
598659.0,"Halozyme Reports Initial Dosing Of Adalimumab Using ENHANCE Technology, Triggers $5M Payment To Halozyme From Abbvie",2016-01-21 08:36:00-05:00,HALO,neutral
598660.0,Mid-Morning Market Update: Markets Down; JPMorgan Beats Q4 Expectations,2016-01-14 10:06:00-05:00,HALO,neutral
598661.0,Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Cyberark Shares Gain Following Merger Chatter,2016-01-13 15:28:00-05:00,HALO,positive
598662.0,Halozyme Sees FY16 Rev. $110-$125M vs. Est. $117.9M,2016-01-11 08:32:00-05:00,HALO,neutral
598663.0,Halozyme Enters $150M Non-Dilutive Royalty-Backed Debt Financing Agreement With ROche & Baxalta,2016-01-04 08:31:00-05:00,HALO,positive
598664.0,"UPDATE: Halozyme Says Will Receive Initial $25M Payment, Followed by Milestone Payments of Up to $160M for Each of Up to Five Collab Targets",2015-12-21 08:32:00-05:00,HALO,neutral
598665.0,"Halozyme Reports Entering of Global Collab, Licensing Deal with Lilly",2015-12-21 08:31:00-05:00,HALO,neutral
598666.0,"Halozyme Therapeutics, Eisai To Give Data Evaluating Antitumor Effects Of PEGPH20 With Eribulin Mesylate In Pre-Clinical Breast Cancer Models",2015-12-09 08:33:00-05:00,HALO,negative
598667.0,Benzinga's Top #PreMarket Gainers,2015-12-04 08:35:00-05:00,HALO,positive
598668.0,Wells Fargo Initiates Coverage on Halozyme Therapeutics at Outperform,2015-12-04 07:50:00-05:00,HALO,positive
598669.0,"Halozyme Shares Recently Make Parabolic Move, Spiking to High at $17.70; Shares Up ~8.7% to $17 At Last Check",2015-11-18 10:09:00-05:00,HALO,positive
598670.0,Benzinga's Top Initiations,2015-11-18 09:34:00-05:00,HALO,positive
598671.0,"Citigroup Initiates Coverage on Halozyme Therapeutics at Buy, Announces $25.00 PT",2015-11-18 09:18:00-05:00,HALO,neutral
598672.0,"Halozyme To Open New San Francisco Office, Expects To Recruit Talent To Help Commercialize New PEGPH20 Drug",2015-11-17 17:01:00-05:00,HALO,positive
598673.0,Halozyme Spikes Higher,2015-11-10 15:32:00-05:00,HALO,neutral
598674.0,Shares Of Halo Spiking,2015-11-10 15:31:00-05:00,HALO,positive
598675.0,Halozyme Sees FY15 Rev. $110-$115M vs. Est. $111.21M,2015-11-09 16:17:00-05:00,HALO,neutral
598676.0,"Halozyme Reports Q3  EPS $(0.19) vs. Est. $(0.16), Rev. $20.8M vs. Est. $24.01M",2015-11-09 16:17:00-05:00,HALO,neutral
598677.0,First Patient Dosed in Clinical Trial of Halozyme Investigational Drug PEGPH20 in Combination With Merck Immuno-oncology Drug KEYTRUDA,2015-11-05 08:37:00-05:00,HALO,neutral
598678.0,Shares of Halozyme Spike to Session High $17.74 Over Last Min; Price Seems to Be Breaking Out Higher Following Consolidation Phase Near $17.25 Support Level,2015-11-04 10:55:00-05:00,HALO,positive
598679.0,Halozyme Reports First Clinical Dosing Of Janssen's Daratumumab Using ENHANZE Technology,2015-11-04 08:31:00-05:00,HALO,neutral
598680.0,Halozyme Reports First Clinical Dosing of Pfizer's Rivipansel Using Enhanze Technology,2015-10-29 08:32:00-04:00,HALO,neutral
598681.0,Benzinga's Top Initiations,2015-09-22 09:00:00-04:00,HALO,positive
598682.0,"Barclays Initiates Coverage on Halozyme Therapeutics at Overweight, Announces $27.00 PT",2015-09-22 04:30:00-04:00,HALO,negative
598683.0,"Halozyme Therapeutics CFO Stelzer Buys 10,000 Shares @$17.24/Share -Form 4",2015-08-24 08:48:00-04:00,HALO,positive
598684.0,Halozyme Names Michael Labarre as Chief Scientific Officer,2015-08-24 08:32:00-04:00,HALO,neutral
598685.0,"Jim Cramer Advises His Viewers On Halozyme Therapeutics, CF Industries And Tower International",2015-08-13 06:34:00-04:00,HALO,neutral
598686.0,Halozyme Raises FY15 Sales Outlook from $85M-$95M to $110M-$115M vs $95.7M Est.,2015-08-10 16:08:00-04:00,HALO,neutral
598687.0,"Halozyme Reports Q2 EPS $0.02 vs Loss of $0.09/Share Est., Sales $43.4M",2015-08-10 16:07:00-04:00,HALO,negative
598688.0,UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery,2015-08-06 12:16:00-04:00,HALO,negative
598689.0,"Eisai, Halozyme Agree To Collaboration On Eribulin & PEGPH20 Metastic Breast Cancer Investigation",2015-07-31 07:55:00-04:00,HALO,negative
598690.0,US Stock Futures Edge Lower Ahead Of Consumer Sentiment Report,2015-07-31 07:39:00-04:00,HALO,negative
598691.0,"Eisai, Halozyme Anounce Collaboration to Investigate Eribulin and Pegph20 in Advanced Breast Cancer",2015-07-31 04:19:00-04:00,HALO,negative
598692.0,Stocks Hitting 52-Week Highs,2015-06-08 10:13:00-04:00,HALO,neutral
598693.0,Schneider Electric Expands Its Partnership With OpenText To Enable Global Supply Chain Platform,2015-06-05 09:01:00-04:00,HALO,positive
598694.0,"Halozyme Announces CFO David Ramsay to Retire This Summer, Laurie Stelzer Named as Replacement",2015-06-05 09:01:00-04:00,HALO,neutral
598695.0,JMP Securities Boosts Halozyme Price Target On 'Long-Term Value',2015-06-04 10:17:00-04:00,HALO,positive
598696.0,"Halozyme, AbbVie Enter Global Partnership And Licensing Agreement; Halozyme To Receive One Time $23M Payment Followed By Milestone Payments Up To $130M",2015-06-03 08:32:00-04:00,HALO,positive
598697.0,Halozyme Presents Promising Phase 2 Findings from Clinical Study of PEGPH20 for Metastatic Pancreatic Cancer Patients,2015-05-31 11:24:00-04:00,HALO,negative
598698.0,"Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment",2015-05-27 08:30:00-04:00,HALO,negative
598700.0,New Drug Could Transform Pancreatic Cancer Treatment,2015-05-18 14:16:00-04:00,HALO,negative
598701.0,"Halozyme Therapeutics Reports Q1 Loss of $0.12/Share vs Loss of $0.13/Share Est., Sales $18.666M vs $19.4M Est.",2015-05-11 16:24:00-04:00,HALO,negative
598702.0,Halozyme Issues New Preclinical Data at ASCO: PEGPH20 Boosted T-Cell Access to Tumor Cells in Animals,2015-04-20 08:17:00-04:00,HALO,neutral
598703.0,"Halozyme Therapeutics Names Harry Leonhardt General Counsel, COO",2015-04-13 09:04:00-04:00,HALO,neutral
598704.0,MLV: We're Reiterating A Buy On Halozyme,2015-04-08 16:36:00-04:00,HALO,neutral
598705.0,Halozyme Therapeutics Spikes Up Following FDA News,2015-04-08 09:46:00-04:00,HALO,neutral
598706.0,"Halozyme Offers Update Following Type B FDA Meeting: Says Will Proceed with Phase 3 PEGPH20, Expecting Commencement of Phase 3 Study By End of Q1'16",2015-04-08 09:16:00-04:00,HALO,neutral
598707.0,"Halozyme Therapeutics Names James Mazzola VP, Corporate Communications And Investor Relations",2015-03-23 09:01:00-04:00,HALO,neutral
598708.0,Halozyme Therapeutics Reports First Product Candidate Selection Under Janssen Collaboration,2015-03-10 09:05:00-04:00,HALO,neutral
598709.0,Halozyme Therapeutics Beats Q4 Views; Outlook Shy Of Consensus,2015-03-02 18:59:00-05:00,HALO,negative
598710.0,"Halozyme Therapeutics Reports Q4 EPS -$0.04 Vs Est -$0.07, Sales $30.4M Vs Est $25.59M",2015-03-02 16:15:00-05:00,HALO,neutral
598711.0,Halozyme Preclinical Study Results of PEGPH20 Published In Molecular Cancer Therapeutics,2015-02-17 08:36:00-05:00,HALO,negative
598712.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,HALO,neutral
598713.0,"Halozyme Reports Update on Anticipated Milestones: Currently Evaluating, Advancing Investigational PEGPH20; Expecting FY Sales $85-$95M",2015-01-12 09:03:00-05:00,HALO,neutral
598714.0,Benzinga's Volume Movers,2015-01-08 10:33:00-05:00,HALO,neutral
598715.0,UPDATE: MLV & Co Raises PT On Halozyme Therapeutics On Promising Start To 2015,2015-01-08 09:36:00-05:00,HALO,positive
598716.0,"UPDATE: Halozyme Shares Rise 27% on Day of Investor, Analyst Meeting",2015-01-07 15:03:00-05:00,HALO,positive
598717.0,Halozyme Closes In On A Breakout: A Technical Analysis,2015-01-07 14:31:00-05:00,HALO,neutral
598718.0,Halozyme Provides Agenda Highlights For Analyst And Investor Meeting,2015-01-07 08:03:00-05:00,HALO,neutral
598719.0,What Investors Are Looking For After Seeing Unusual Options Activity In Halozyme,2015-01-06 12:15:00-05:00,HALO,neutral
598720.0,"Option Alert: Halozyme Jan $11 Call; 2,000 Contract Trade at Ask @$0.25; Currently $10.08",2015-01-05 15:52:00-05:00,HALO,positive
598721.0,Benzinga's Top Initiations,2014-12-24 09:08:00-05:00,HALO,positive
598722.0,MLV & Co Initiates Halozyme Therapeutics With Buy,2014-12-24 07:11:00-05:00,HALO,neutral
598723.0,US Stock Futures Edge Higher; Jobless Claims Data In Focus,2014-12-24 07:03:00-05:00,HALO,neutral
598724.0,"MLV & Co.  Initiates Coverage on Halozyme Therapeutics at Buy, Announces $12.00 PT",2014-12-24 05:29:00-05:00,HALO,neutral
598725.0,Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20,2014-12-19 08:30:00-05:00,HALO,neutral
598726.0,"Halozyme Announces Global Collaboration with J&J's Janssen for Development, Commercialization of Subcutaneous Products Using ENHANZE Technology",2014-12-17 09:04:00-05:00,HALO,neutral
598727.0,Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting,2014-12-12 08:03:00-05:00,HALO,negative
598728.0,Halozyme Therapeutics Plummets On Q3 Losses,2014-11-10 17:19:00-05:00,HALO,negative
598729.0,Flash: Afterhour Movers: LLNW up 8%; HALO down 14.16%;,2014-11-10 16:22:00-05:00,HALO,neutral
598730.0,"Halozyme Therapeutics, Inc. Reports Q3 EPS of $(0.16) vs $(0.14) Est; Revenue of $14.60M vs $16.45M Est",2014-11-10 16:06:00-05:00,HALO,neutral
598731.0,"Earnings Scheduled For November 10, 2014",2014-11-10 05:36:00-05:00,HALO,neutral
598732.0,"8-K from Halozyme Shows VP, General Counsel, Secretary Jean Liu Resigned",2014-10-24 17:04:00-04:00,HALO,negative
598733.0,Baxter Reports Launch of HYQVIA in US for Adults with Primary Immunodeficiency,2014-10-20 09:03:00-04:00,HALO,neutral
598734.0,Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex Recombinant ,2014-10-20 08:30:00-04:00,HALO,positive
598735.0,Halozyme Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20 ,2014-10-07 08:35:00-04:00,HALO,neutral
598736.0,UPDATE: Halozyme Receives Orphan Drug Designation For Pancreatic Cancer Treatment,2014-10-03 07:46:00-04:00,HALO,negative
598737.0,Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer ,2014-10-03 07:45:00-04:00,HALO,negative
598738.0,Halozyme Wins Orphan Drug Designation for Pancreatic Cancer Treatment,2014-10-02 17:02:00-04:00,HALO,negative
598739.0,Halozyme Announces SWOG Will Resume Clinical Trial of PEGPH20 In Combo with Modified FOLFIRINOX for Advanced Pancreatic Cancer,2014-09-18 09:04:00-04:00,HALO,negative
598740.0,Morning Market Movers ,2014-09-15 09:42:00-04:00,HALO,neutral
598741.0,Benzinga's Top #PreMarket Gainers,2014-09-15 08:06:00-04:00,HALO,positive
598742.0,Halozyme Shares Rise 9% Premarket Following FDA Approval of HYQVIA,2014-09-15 07:33:00-04:00,HALO,positive
598743.0,Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation,2014-09-03 08:35:00-04:00,HALO,negative
598744.0,"Halozyme Therapeutics, Inc. Reports Q2 EPS of $(0.13) vs $(0.14) Est",2014-08-11 16:15:00-04:00,HALO,neutral
598745.0,Halozyme Therapeutics Receives Favorable FDA Decision,2014-07-31 14:45:00-04:00,HALO,positive
598746.0,"Shares of Halozyme Resume Trade, Stock Now Up 10.3%",2014-07-31 14:25:00-04:00,HALO,positive
598747.0,PREVIEW: Halozyme Therapeutics to Resume Trading at 2:25 PM ET,2014-07-31 14:01:00-04:00,HALO,neutral
598748.0,FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's Hyqvia ror Primary Immunodeficiency;  Expects FDA Response In Q3,2014-07-31 13:56:00-04:00,HALO,positive
598749.0,Halozyme Shares Halted News Pending,2014-07-31 06:57:00-04:00,HALO,positive
598750.0,"Halozyme Announces Resumption of Patient Enrollment, Dosing in PEGPH20 Clinical Trial",2014-07-22 09:02:00-04:00,HALO,neutral
598751.0,Benzinga's Top Initiations,2014-07-11 09:18:00-04:00,HALO,positive
598752.0,JP Morgan Initiates Halozyme Therapeutics With Outperform,2014-07-11 07:54:00-04:00,HALO,positive
598753.0,"JP Morgan Initiates Coverage on Halozyme Therapeutics, Inc. at Outperform, Announces $13.00 PT",2014-07-11 07:32:00-04:00,HALO,positive
598754.0,Benzinga's Top #PreMarket Gainers,2014-06-25 08:11:00-04:00,HALO,positive
598755.0,"Halozyme Announces Commercial Launch of Roche's MabThera SC Triggers Milestone Payment, Co. Will Receive $5M",2014-06-25 08:05:00-04:00,HALO,neutral
598756.0,"UBS Upgrades Halozyme Therapeutics, Inc. to Buy",2014-06-11 16:29:00-04:00,HALO,neutral
598757.0,Mid-Day Market Update: US Stocks Surge; PVH Shares Slip On Downbeat Results,2014-06-05 14:52:00-04:00,HALO,positive
598758.0,Shares Of Halozyme Up 14% Following FDA Removal Of Hold On PEGPH20,2014-06-05 11:29:00-04:00,HALO,positive
598759.0,Morning Market Movers ,2014-06-05 09:40:00-04:00,HALO,neutral
598760.0,Benzinga's Top #PreMarket Gainers,2014-06-05 08:10:00-04:00,HALO,positive
598761.0,Halozyme Announces Will Resume PEGPH20 in Pancreatic Cancer,2014-06-04 16:06:00-04:00,HALO,negative
598762.0,"Option Alert: Halozyme Sep $12 Call; 1,000 Contracts Traded vs 400 OI; Currently $8.20",2014-05-29 10:47:00-04:00,HALO,positive
598763.0,Mid-Afternoon Market Update: Markets Trade In Choppy Session As Elizabeth Arden Shares Remain Down,2014-05-13 15:44:00-04:00,HALO,positive
598764.0,"Mid-Day Movers: GORO, HALO, COCO, UEC, EVDY Moving Higher; RDEN, CALL, DXPE, FTEK Lower",2014-05-13 15:38:00-04:00,HALO,negative
598765.0,Mid-Day Market Update: Rackspace Gains On Upbeat Earnings; DXP Enterprises Shares Slip,2014-05-13 12:40:00-04:00,HALO,positive
598766.0,Mid-Morning Market Update: Markets Gain; Elizabeth Arden To Explore Strategic Alternatives,2014-05-13 10:28:00-04:00,HALO,positive
598767.0,Morning Market Movers ,2014-05-13 09:38:00-04:00,HALO,neutral
598768.0,Benzinga's Top #PreMarket Gainers,2014-05-13 08:06:00-04:00,HALO,positive
598769.0,"Halozyme Therapeutics, Inc. Reports Q1 EPS of $(0.22) vs $(0.14) Est",2014-05-12 16:15:00-04:00,HALO,neutral
598770.0,Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View,2014-04-15 10:27:00-04:00,HALO,positive
598771.0,Morning Market Movers ,2014-04-15 09:43:00-04:00,HALO,neutral
598772.0,Benzinga's Top #PreMarket Gainers,2014-04-15 08:09:00-04:00,HALO,positive
598773.0,Benzinga's Top Initiations,2014-04-15 07:56:00-04:00,HALO,positive
598774.0,"Citigroup Initiates Coverage on Halozyme Therapeutics, Inc. at Buy, Announces $12.00 PT",2014-04-15 07:27:00-04:00,HALO,neutral
598775.0,Markets Falling? Get Your Defense Ready,2014-04-14 15:47:00-04:00,HALO,positive
598776.0,Morning Market Losers ,2014-04-09 09:48:00-04:00,HALO,negative
598777.0,Benzinga's Top #PreMarket Losers,2014-04-09 08:14:00-04:00,HALO,negative
598778.0,UPDATE: Halozyme Reports Clinical Hold of PEGPH20 Pancreatic Cancer Trial Amid Voluntary Halt,2014-04-09 08:07:00-04:00,HALO,negative
598779.0,Halozyme Reports Clinical Hold of PEGPH20 Pancreatic Cancer Trial Amid Voluntary Halt,2014-04-09 08:00:00-04:00,HALO,negative
598780.0,Biotechs Struggling To Find A Bottom,2014-04-08 10:24:00-04:00,HALO,negative
598781.0,Halozyme Announces Preclinical Data Presentations At The Association Of Cancer Research Annual Meeting,2014-04-08 09:05:00-04:00,HALO,negative
598782.0,"Market Wrap For April 4: Dow Suffers Triple Digit Point Loss, Nasdaq Continues To Underperform",2014-04-04 16:44:00-04:00,HALO,negative
598783.0,"Mid-Afternoon Market Update: Markets Drop, Lead Lower by NASDAQ Momentum Names",2014-04-04 15:47:00-04:00,HALO,negative
598784.0,Mid-Day Market Update: NASDAQ Tumbles 1.8%; SYNNEX Shares Gain After Upbeat Results,2014-04-04 12:55:00-04:00,HALO,positive
598785.0,Mid-Morning Market Update: Markets Mixed; CarMax Results Miss Estimates,2014-04-04 10:14:00-04:00,HALO,negative
598786.0,Benzinga's Top #PreMarket Losers,2014-04-04 08:22:00-04:00,HALO,negative
598787.0,UPDATE: Halozyme Announces Temporary Halt of Phase 2 Trial Enrollment,2014-04-04 08:02:00-04:00,HALO,neutral
598788.0,Halozyme Announces Temporary Halt of Phase 2 Trial Enrollment,2014-04-04 08:01:00-04:00,HALO,neutral
598789.0,"Form 8-K from Halozyme Shows' Co.'s VP, Commercial Cheif James Shaffer Has Resigned",2014-04-03 16:12:00-04:00,HALO,negative
598790.0,"Halozyme Names Sunil Joshi as VP, Global Product Team Lead for PEGPH20, Oncology",2014-04-02 08:14:00-04:00,HALO,neutral
598791.0,Mid-Morning Market Update: Markets Open Higher; UTi Worldwide Reports Q4 Loss,2014-03-31 10:35:00-04:00,HALO,negative
598792.0,Morning Market Movers ,2014-03-31 09:40:00-04:00,HALO,neutral
598793.0,Halozyme Consistent 1 Trial Of Hylenex(R) Recombinant Met Primary Endpoint,2014-03-31 08:01:00-04:00,HALO,neutral
598794.0,Halozyme Announces Roche Marketing Authorization or MabThera SC For Patients With Common Forms Of Non-Hodgkin Lymphoma In EU,2014-03-28 08:01:00-04:00,HALO,neutral
598795.0,Halozyme Announces Positive Results from Phase 1/2 Clinical Trial in Cellulite with HTI-501,2014-03-25 08:01:00-04:00,HALO,positive
598796.0,"Mid-Afternoon Market Update: Markets Take a Sharp Dip to the Downside, as Traders Take Month-End Profits",2014-02-28 16:00:00-05:00,HALO,positive
598797.0,"Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr",2014-02-28 10:40:00-05:00,HALO,neutral
598798.0,"Halozyme Therapeutics, Inc. Reports Q4 EPS of $(0.19) vs $(0.17) Est",2014-02-27 16:15:00-05:00,HALO,neutral
598799.0,Halozyme Therapeutics Announces Public Offering of ~8.846M Shares,2014-02-10 16:15:00-05:00,HALO,positive
598800.0,Halozyme Therapeutics Prices 7.692M Share Offering at $13.00/Share ,2014-02-04 21:30:00-05:00,HALO,positive
598801.0,Halozyme Therapeutics Plans $100M Public Offering,2014-02-03 16:03:00-05:00,HALO,neutral
598802.0,Halozyme Announces Positive Opinion From CHMP for Roche's MabThera SC ,2014-01-24 11:36:00-05:00,HALO,positive
598803.0,"Form 8-K from Halozyme Shows Amended Credit Pact, Extends Original Loans, Provides Added $20M in Liquidity",2014-01-03 16:41:00-05:00,HALO,positive
598804.0,UPDATE: Halozyme Spikes Higher on Positive CNBC Comments,2013-12-18 12:56:00-05:00,HALO,positive
598805.0,Halozyme Spikes Higher,2013-12-18 12:54:00-05:00,HALO,neutral
598806.0,"Option Alert: Halozyme January $15 Call; 6,010 Contracts Traded Wednesday vs 279 Open Interest; Currently $13.14",2013-12-18 09:48:00-05:00,HALO,positive
598807.0,"Baxter Submits Amended BLA to FDA for Hyqvia for Primary Immunodeficiency, Baxter, Halozyme Expecting Six-Month Review",2013-12-02 09:01:00-05:00,HALO,neutral
598808.0,Halozyme Spikes to High,2013-11-08 11:54:00-05:00,HALO,neutral
598809.0,"Option Alert; Halozyme Therapeutics December 12 Call; 2,138 Contracts Traded @$1.17; Currently $11.37",2013-10-16 14:23:00-04:00,HALO,positive
598810.0,Halozyme Receives Milestone Payment of $10M from Roche Following Commercial Launch of Herceptin SC,2013-09-26 16:26:00-04:00,HALO,neutral
598811.0,Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in EU,2013-09-02 11:25:00-04:00,HALO,neutral
598812.0,"Halozyme Therapeutics, Inc. Reports Q2 EPS of $(0.20) vs $(0.13) Est",2013-08-07 16:06:00-04:00,HALO,neutral
598813.0,"Barclays Downgrades Halozyme Therapeutics, Inc. to Equalweight, Lowers PT to $8.00",2013-08-02 08:06:00-04:00,HALO,negative
598814.0,"Benzinga Market Wrap for Thursday, August 1: Record Highs!",2013-08-01 16:59:00-04:00,HALO,neutral
598815.0,Mid-Afternoon Market Update: Trulia Rises as Hanger Drops on its Second-Quarter Results,2013-08-01 15:56:00-04:00,HALO,neutral
598816.0,"Mid-Day Market Update: Yelp Surges On Narrower Loss, SunPower Shares Decline",2013-08-01 12:41:00-04:00,HALO,neutral
598817.0,"Mid-Morning Market Update: Markets Rally, Procter & Gamble Earnings Top Estimates",2013-08-01 10:49:00-04:00,HALO,positive
598818.0,Halozyme Issued Update on ViroPharma Phase 2 Trial of C1 Esterase Inhibitor Formulation with rHuPH20,2013-08-01 08:25:00-04:00,HALO,negative
598819.0,Benzinga's Top Pre-Market Losers,2013-08-01 08:25:00-04:00,HALO,negative
598820.0,Edison Investment Research Comments on Halozyme Therapeutics on Multiple Value Drivers,2013-07-05 10:17:00-04:00,HALO,positive
598821.0,"BMO Says Biotech Sector Could See Upside from M&A, Offers Multiple Attractive Targets",2013-07-02 12:29:00-04:00,HALO,positive
598822.0,Halozyme Presents Positive Phase 2 HTI-501 Data ,2013-06-30 18:08:00-04:00,HALO,positive
598823.0,Afternoon Market Gainers,2013-06-28 12:43:00-04:00,HALO,neutral
598824.0,Halozyme Spikes Higher,2013-06-28 11:40:00-04:00,HALO,neutral
598825.0,Halozyme Announces Positive Opinion from CHMP on Roche's Herceptin SC for European Approval,2013-06-28 11:40:00-04:00,HALO,positive
598826.0,Halozyme Therapeutics Announces Positive Opinion from CHMP On Roche's Herceptin SC for European Approval,2013-06-28 11:37:00-04:00,HALO,positive
598827.0,"Option Alert: Halozyme Therapeutics July 10 Call; Block Trade: 4,500 Contracts @$0.30, Currently $7.03",2013-05-23 09:40:00-04:00,HALO,negative
598828.0,Halozyme Names David Ramsay CFO,2013-05-23 08:00:00-04:00,HALO,neutral
598829.0,Mid-Afternoon Market Update: Optimer Falls as Halozyme Rockets Upwards,2013-05-16 15:35:00-04:00,HALO,neutral
598830.0,"Mid-Day Market Update: US Stocks Fluctuate, Cisco Systems Up on Better-than-Expected Earnings",2013-05-16 13:38:00-04:00,HALO,neutral
598831.0,"Mid-Morning Market Update: Housing Starts Plummet, Initial Jobless Claims Rise",2013-05-16 10:51:00-04:00,HALO,neutral
598832.0,UPDATE: Piper Jaffray Initiates Halozyme Therapeutics at Overweight on Potential Value Drivers,2013-05-15 06:30:00-04:00,HALO,neutral
598833.0,"Piper Jaffray Initiates Coverage on Halozyme Therapeutics, Inc. at Overweight, Announces $10.00 PT",2013-05-14 16:10:00-04:00,HALO,negative
598834.0,"Halozyme Therapeutics, Inc. Reports Q1 EPS of $(0.17) vs $(0.15) Est; Revenue of $11.80M vs $7.05M Est",2013-05-08 17:00:00-04:00,HALO,neutral
598835.0,"UBS Maintains Neutral on Halozyme Therapeutics, Inc., Lowers PT to $6.50",2013-05-01 10:16:00-04:00,HALO,negative
598836.0,Halozyme Names Matt Posard to Board,2013-03-28 16:21:00-04:00,HALO,neutral
598837.0,"Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR)",2013-03-23 11:33:00-04:00,HALO,positive
598838.0,"Market Wrap for Friday, March 22: Stocks Rise on Hopes of Bailout Deal for Cyprus",2013-03-22 16:17:00-04:00,HALO,positive
598839.0,"Mid-Day Market Update: Micron Surges On Upbeat Revenue, Informatica Declines",2013-03-22 13:23:00-04:00,HALO,neutral
598840.0,Baxter and Halozyme Announce Positive Opinion for HyQvia for Treatment of Primary and Secondary Immunodeficiencies in the European Union ,2013-03-22 08:31:00-04:00,HALO,positive
598841.0,"Option Alert: Halozyme Therapeutics June 7.5 Call; Block Trade: 4,200 Contracts Traded @$0.65, Currently $5.98",2013-03-11 09:49:00-04:00,HALO,negative
598842.0,"UPDATE: BMO Capital Markets Reiterates Outperform Rating, Lowers PT on Halozyme Therapeutics",2013-02-01 10:32:00-05:00,HALO,negative
598843.0,"BMO Capital Maintains Outperform on Halozyme Therapeutics, Inc., Lowers PT to $9.00",2013-02-01 08:35:00-05:00,HALO,negative
598844.0,Halozyme Therapeutics Spikes to Lows,2013-01-30 15:05:00-05:00,HALO,negative
598845.0,"Wedbush Downgrades Halozyme Therapeutics, Inc. to Neutral, Lowers PT to $13.00",2013-01-30 14:42:00-05:00,HALO,negative
598846.0,"Jefferies Reiterates Underperform Rating, $4 PT on Halozyme Therapeutics",2013-01-30 09:09:00-05:00,HALO,neutral
598847.0,One Biotech Stock Investors are Unfairly Ignoring,2013-01-15 09:00:00-05:00,HALO,negative
598848.0,"Mid-Afternoon Market Update: Herbalife Rises Above Ackman's Top, SunPower Remains Down",2013-01-14 15:57:00-05:00,HALO,positive
598849.0,"UPDATE: BMO Capital Markets Upgrades Halozyme Therapeutics to Outperform, Raises PT",2013-01-14 10:46:00-05:00,HALO,neutral
598850.0,"BMO Capital Upgrades Halozyme Therapeutics, Inc. to Outperform, Raises to $12.00",2013-01-14 07:52:00-05:00,HALO,neutral
598851.0,"Halozyme Sees 2013 Cash Burn $45-50M, Cash Balance ~$100M",2013-01-07 07:58:00-05:00,HALO,neutral
598852.0,Halozyme Soars After Announcing Deal With Pfizer ,2012-12-21 16:02:00-05:00,HALO,neutral
598853.0,"Mid-Afternoon Update: Herbalife Takes a Bigger Beating, Markets Still Red",2012-12-21 15:54:00-05:00,HALO,negative
598854.0,Benzinga's Top Pre-Market Gainers,2012-12-21 08:24:00-05:00,HALO,positive
598855.0,UPDATE: Halozyme Shares Now Up ~18% Following Resumption,2012-12-21 08:08:00-05:00,HALO,positive
598856.0,Shares of Halozyme Resume Trading Up ~4%,2012-12-21 08:04:00-05:00,HALO,positive
598857.0,PREVIEW: Halozyme Therapeutics to Resume Trading at 8:05 AM ET,2012-12-21 07:44:00-05:00,HALO,neutral
598858.0,"Halozyme Therapeutics, Pfizer Collaborate to Develop And Commercialize Subcutaneous Biologics",2012-12-21 07:40:00-05:00,HALO,neutral
598859.0,Halozyme Halted; Pending News,2012-12-21 07:34:00-05:00,HALO,neutral
598860.0,Halozyme Announces Roche Filing to European Medicines Agency Triggers $4M Milestone Payment,2012-12-08 10:21:00-05:00,HALO,neutral
598861.0,"Barclays Maintains Halozyme Therapeutics at Overweight, Lowers PT from $10 to $9",2012-11-09 14:30:00-05:00,HALO,negative
598862.0,Halozyme Therapeutics Reports Q3 EPS $-0.18 vs $-0.14 Est; Revenues $5.3M vs $6.09M Est,2012-11-08 16:29:00-05:00,HALO,neutral
598863.0,"Wedbush Securities Maintains Halozyme Therapeutics at Outperform, Raises PT from $13 to $17",2012-10-08 13:29:00-04:00,HALO,positive
598864.0,Hearing Wedbush Raises PT on Halozyme to $17; Remains on Best Ideas List,2012-10-08 12:35:00-04:00,HALO,positive
598865.0,"UBS Initiates Coverage on Halozyme Therapeutics at Neutral, Announces PT of $8",2012-09-27 11:15:00-04:00,HALO,neutral
598866.0,"Benzinga's M&A Chatter for Wednesday September 26, 2012",2012-09-26 19:23:00-04:00,HALO,neutral
598867.0,"Barclays Maintains Halozyme Therapeutics at Overweight, Raises PT from $8 to $10",2012-09-24 13:11:00-04:00,HALO,negative
598868.0,"Jefferies & Company Maintains Halozyme Therapeutics at Underperform, Raises PT from $3 to $4",2012-09-24 06:37:00-04:00,HALO,neutral
598869.0,Benzinga Mid-Afternoon Market Update ,2012-09-21 15:16:00-04:00,HALO,neutral
598870.0,"Jefferies & Company Maintains Halozyme Therapeutics at Underperform, Raises PT from $3 to $4",2012-09-21 14:51:00-04:00,HALO,neutral
598871.0,Benzinga Mid-Day Market Update ,2012-09-21 13:06:00-04:00,HALO,neutral
598872.0,Benzinga Mid-Morning Market Update,2012-09-21 10:41:00-04:00,HALO,neutral
598873.0,"ViroPharma, Halozyme Resume Trading",2012-09-21 07:30:00-04:00,HALO,neutral
598874.0,"PREVIEW: ViroPharma, Halozyme to Resume Trading at 7:30am",2012-09-21 07:18:00-04:00,HALO,neutral
598875.0,ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) ,2012-09-21 07:07:00-04:00,HALO,negative
598876.0,"ViroPharma, Halozyme Therapeutics Halted on FDA News",2012-09-21 07:05:00-04:00,HALO,neutral
598877.0,Halozyme Spokesperson Says Can't Speculate on What's Driving Trading,2012-09-06 15:01:00-04:00,HALO,neutral
598878.0,"Option Alert: Halozyme Call Volume at 1,425% of Average; Currently $6.10",2012-09-06 13:30:00-04:00,HALO,positive
598879.0,Halozyme Therapeutics Reports Q2 EPS $-13 vs $-0.15 Est; Revenues $7.76M vs $5.22M Est,2012-08-06 16:13:00-04:00,HALO,neutral
598880.0,"Barclays Maintains Halozyme Therapeutics at Overweight, Lowers PT from $15 to $8",2012-08-02 12:37:00-04:00,HALO,negative
598881.0,UPDATE: Jefferies Downgrades Halozyme Therapeutics to Underperform on FDA Headwinds  ,2012-08-02 10:32:00-04:00,HALO,neutral
598882.0,"Jefferies & Company Downgrades Halozyme Therapeutics from Hold to Underperform, Lowers PT from $8 to $3",2012-08-02 05:50:00-04:00,HALO,negative
598883.0,Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA ,2012-08-01 16:10:00-04:00,HALO,neutral
598884.0,Halozyme's Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes,2012-06-11 18:51:00-04:00,HALO,positive
598885.0,Wedbush Reiterates Outperform Rating for Halozyme Therapeutics,2012-06-11 11:50:00-04:00,HALO,neutral
598886.0,Wedbush Reiterates Outperform and Best Idea Rating on Halozyme Therapeutics,2012-06-11 07:07:00-04:00,HALO,positive
598887.0,"Option Alert: Halozyme Therapeutics June 10 Call; Block Trade: 4,700 Contracts; Currently $8.41",2012-06-06 12:08:00-04:00,HALO,negative
598888.0,Halozyme Therapeutics Reports Q1 EPS $-0.14 vs $-0.11 Est; Revenues $7.4M vs $7.31M Est,2012-05-07 16:23:00-04:00,HALO,neutral
598889.0,Wedbush: FDA Undisclosed Concerns; Halozyme Therapeutics FV Reduced,2012-04-17 09:45:00-04:00,HALO,neutral
598890.0,UPDATE: Jefferies Cuts PT to $8 on Halozyme Therepeutics ,2012-04-17 07:20:00-04:00,HALO,negative
598891.0,"Wedbush Securities Maintains Halozyme Therapeutics at Outperform, Lowers PT from $17 to $16",2012-04-17 06:58:00-04:00,HALO,positive
598892.0,"Jefferies & Company Maintains Halozyme Therapeutics at Hold, Lowers PT from $10 to $8",2012-04-17 06:39:00-04:00,HALO,negative
598893.0,"Jefferies & Company Maintains Halozyme Therapeutics at Hold, Lowers PT from $10 to $8",2012-04-17 06:23:00-04:00,HALO,negative
598894.0,"Brean Murray Carret & Co. Maintains Halozyme Therapeutics at Buy, Lowers PT from $13 to $11",2012-04-16 09:58:00-04:00,HALO,negative
598895.0,Morning Market Losers,2012-04-16 09:56:00-04:00,HALO,negative
598896.0,Halozyme Therapeutics Resumes Trading,2012-04-16 08:30:00-04:00,HALO,neutral
598897.0,PREVIEW: Halozyme Therapeutics to Resume Trading at 8:30am,2012-04-16 08:10:00-04:00,HALO,neutral
598898.0,Baxter and Halozyme Provide Update on HyQ Biologics License Application ,2012-04-16 08:01:00-04:00,HALO,neutral
598899.0,Halozyme Therapeutics Halted for Pending News ,2012-04-16 07:58:00-04:00,HALO,neutral
598900.0,"Financial Breakfast: Morning News Summary for April 10, 2012",2012-04-10 07:26:00-04:00,HALO,neutral
598901.0,Benzinga's Top Downgrades,2012-04-10 07:24:00-04:00,HALO,positive
598902.0,UPDATE: Jefferies Downgrades Halozyme Therapeutics to Hold ,2012-04-10 07:09:00-04:00,HALO,neutral
598903.0,"Jefferies & Company Downgrades Halozyme Therapeutics from Buy to Hold, Maintains PT at $10",2012-04-10 06:02:00-04:00,HALO,neutral
598904.0,Oppenheimer Anticipating FDA Approval of HyQvia,2012-03-12 08:27:00-04:00,HALO,positive
598905.0,Earnings Scheduled For March 9,2012-03-09 04:47:00-05:00,HALO,neutral
598906.0,ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze with Recombinant Human Hyaluronidase ,2012-03-06 09:45:00-05:00,HALO,positive
598907.0,Halozyme Announces Pricing of 6.8M Share Public Offering at $10.61 ,2012-02-10 08:36:00-05:00,HALO,positive
598908.0,Halozyme Announces Proposed Public Offering of Common Stock; 6.8M Shares,2012-02-09 16:17:00-05:00,HALO,positive
598909.0,Halozyme Therapeutics Announces HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial ,2012-01-31 16:06:00-05:00,HALO,positive
598910.0,Weekly Homework: In Search Of The Santa Claus Rally (w/ Economic Calendar & Stock Radar),2011-12-11 23:22:00-05:00,HALO,neutral
598911.0,"Wedbush Reiterates Outperform, $17 PT On Halozyme Therapeutics",2011-12-07 09:03:00-05:00,HALO,neutral
598912.0,ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze,2011-12-06 08:05:00-05:00,HALO,positive
598913.0,UPDATE: Wedbush Raises Price Target on Halozyme to $17,2011-11-09 09:03:00-05:00,HALO,neutral
598914.0,"Wedbush Raises PT on Halozyme to $17, Adds to Best Ideas List",2011-11-09 08:46:00-05:00,HALO,positive
598915.0,Halozyme Therapeutics Announces Positive Results from Enzyme-Augmented Insulin Pump Trial,2011-10-27 19:19:00-04:00,HALO,positive
598916.0,Notable Call Options Activity in Halozyme Therapeutics,2011-10-24 10:51:00-04:00,HALO,neutral
598917.0,Oppenheimer Outperform on Halozyme Therapeutics,2011-10-21 15:31:00-04:00,HALO,neutral
598918.0,Halozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials in Patients with Type 1 and Type 2 Diabetes  ,2011-10-21 08:01:00-04:00,HALO,positive
598919.0,"End-of-Day Market Summary for October 18, 2011",2011-10-18 16:15:00-04:00,HALO,neutral
598920.0,Afternoon Gainers; Housing Stocks up on Upbeat NAHB Data,2011-10-18 15:42:00-04:00,HALO,neutral
598921.0,UPDATE: Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial ,2011-10-18 10:31:00-04:00,HALO,positive
598922.0,"Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer  ",2011-10-05 08:02:00-04:00,HALO,negative
598923.0,Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy  ,2011-09-28 08:01:00-04:00,HALO,neutral
598924.0,ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze,2011-09-13 15:04:00-04:00,HALO,neutral
598925.0,Baxter and Halozyme Announce Top-Line Results of Phase III Study of HyQ in Patients with Primary Immunodeficiency   ,2011-07-08 08:39:00-04:00,HALO,neutral
598926.0,"Morning News Summary For May 11, 2011",2011-05-11 09:59:00-04:00,HALO,neutral
598927.0,"Benzinga's Top Pre-Market NASDAQ Gainers (ROVI, ASYS, ZAGG, HALO)",2011-05-11 08:19:00-04:00,HALO,positive
598928.0,Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze,2011-05-11 07:29:00-04:00,HALO,positive
598929.0,Stifel Nicolaus Initiates Coverage on Halozyme Thearapeutics at Buy (HALO),2011-04-01 09:14:00-04:00,HALO,neutral
598930.0,"Wedbush Says HALO Is ""No Fallen Angel""",2011-03-23 08:00:00-04:00,HALO,negative
598931.0,Halozyme Therapeutics Reports Q4 EPS of $(0.17) vs. $(0.12),2011-03-11 07:31:00-05:00,HALO,neutral
598932.0,"Earnings Scheduled For March 11 (AWR, HIBB, BIOS, ANN, ARNA, LMIA, HALO, UTSI, PKT, NGPC, SNTA)",2011-03-11 03:12:00-05:00,HALO,neutral
598933.0,Halozyme Therapeutics to Host Q4 and 2010 Financial Results Conference Call on March 11 ,2011-03-04 07:47:00-05:00,HALO,neutral
598934.0,"Halozyme Therapeutics CEO, President Resigns",2010-12-03 07:32:00-05:00,HALO,negative
598935.0,Jefferies Has Note On Halozyme Therapeutics (HALO),2010-11-08 07:31:00-05:00,HALO,neutral
598936.0,Halozyme Therapeutics Reports Third Quarter EPS of $(0.13),2010-11-05 07:36:00-04:00,HALO,neutral
598937.0,A Peek Into The Market Before The Trading Starts,2010-11-04 08:00:00-04:00,HALO,neutral
598938.0,Halozyme Therapeutics Awarded Four Qualifying Therapeutic Discovery Project Grants ,2010-11-04 07:46:00-04:00,HALO,positive
598939.0,Halozyme Reveals New Development Plans,2010-10-15 08:22:00-04:00,HALO,neutral
598940.0,Hallozyme Partners With Ph3 Products In Product Development,2010-10-15 08:11:00-04:00,HALO,neutral
598941.0,Halozyme Therapeutics To Cut 25% of Its Workforce (HALO),2010-10-11 16:14:00-04:00,HALO,negative
598942.0,Halozyme Therapeutics Announces Implementation of Development Strategy ,2010-10-11 16:06:00-04:00,HALO,neutral
598943.0,A Peek Into The Market Before The Trading Starts,2010-09-09 09:26:00-04:00,HALO,neutral
598944.0,Halozyme Therapeutics Announces Pricing of Public Offering ,2010-09-09 09:04:00-04:00,HALO,neutral
598945.0,Halozyme Therapeutics Announces Public Offering of 8.3 Million Shares,2010-09-08 16:10:00-04:00,HALO,positive
598946.0,Jefferies Reiterates Buy On Halozyme Therapeutics After In-Line 2Q Loss (HALO),2010-08-09 12:26:00-04:00,HALO,negative
598947.0,6-29-10 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com,2010-06-29 12:06:00-04:00,HALO,neutral
598948.0,Drug Recall to Negatively Impact Halozyme: Retains ‘Outperform’ Rating At Oppenheimer (HALO) ,2010-06-07 12:12:00-04:00,HALO,neutral
598949.0,Halozyme Announces Recall,2010-05-17 09:29:00-04:00,HALO,neutral
598950.0,Halozyme Announces Recall,2010-05-17 09:27:00-04:00,HALO,neutral
598951.0,Phase III Development Of Drug Candidates By HALO To Boost Shareholder Value,2010-04-08 11:14:00-04:00,HALO,positive
598952.0,"Benzinga’s Top Upgrades (UNFI, AGP, HALO, PPS, FSP)",2010-03-22 12:23:00-04:00,HALO,positive
598953.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,HALO,positive
598954.0,"Benzinga’s News Roundup (HALO, LACO, ANN, ARNA)",2010-03-12 08:16:00-05:00,HALO,neutral
598955.0,Monday's Hot Stocks: Charge Up Your Portfolio With Volterra,2010-03-02 10:06:00-05:00,HALO,neutral
598956.0,"TSX Venture Exchange Daily Bulletins for August 12, 2009",2009-08-12 17:03:00-04:00,HALO,neutral
